Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
Osteoporosis International, 10/13/09

Bruyère O et al. – Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.

Methods

From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) assessed at baseline and after 3 months
2373 women included

Results

Multiple regression analysis showed 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I significantly associated with 3-year BMD changes at lumbar spine and femoral neck
Changes in s-CTX I, PICP and BALP significantly associated with change in total proximal femur BMD
Changes in biochemical markers explain < 8% of BMD changes
3-month changes in BALP, PICP s-CTX I and s-NTX I not significantly associated with fracture incidence

<< Previous
Bone mineral density and fractures in older men with chronic...

Next >>
The ITGAV rs3738919 variant and susceptibility to rheumatoid...